The molecular cytogenetics market is consolidated in nature due to the presence of a few large players. The prominent players in the market include F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), PerkinElmer, Inc. (U.S.), Illumina, Inc. (U.S.), Bio-Rad Laboratories (U.S.), Oxford Gene Technology (U.K.), and Applied Spectral Imaging (U.S.).
F. Hoffmann-La Roche Ltd. (Switzerland) was the largest player in the global molecular cytogenetics market, with a share of 15.2% in 2015. The company has a strong presence in the U.S. and in regions such as Europe, the Middle East, and Africa (EMEA), Asia-Pacific, Latin America, and Japan. It focuses on acquisition as its key growth strategy. For instance, in January 2014, Roche acquired Genia Technologies, Inc. (U.S.). This acquisition strengthened Roche's next-generation sequencing pipeline. Moreover, in February 2015, Roche acquired Signature Diagnostics AG (Germany). This acquisition allowed Roche to further develop non-invasive treatment and monitoring devices for cancer patients.
Danaher Corporation (U.S.) was the second-largest player, with a market share of 13.7% in 2015. Leica Microsystems is a subsidiary of Danaher that develops molecular cytogenetics instruments and kits. The company has plants in Germany, Austria, Switzerland, the U.K., China, and Singapore. It has presence in over 100 countries—with sales and service organizations in 20 countries and an international network of distribution partners. The company focuses on the introduction of innovative and technologically advanced products in the market.
Thermo Fisher Scientific, Inc. (U.S.) was the third-largest market player, with a share of 12.7% in 2015. The company operates in over 50 countries across North America, Europe, Asia, and Latin America. The company focuses on agreements and acquisitions to strengthen its market presence. For instance, in January 2016, Thermo Fisher acquired Affymetrix (U.S.) to strengthen its leadership in the bioscience business and create new market opportunities in genetic analysis. Moreover, in July 2016, Thermo Fisher and China-based HEALTH BioMed (HBM) collaborated to support HBM’s development of molecular diagnostic kits for infectious diseases and pharmacogenomics screening which will serve the Chinese market.
The key strategies followed by most companies in the molecular cytogenetics market are expansions, acquisitions, agreements, partnerships and collaboration. Agreements, partnerships and collaboration accounted for the largest share in molecular cytogenetics market. Some of the leading players that adopted this strategy include Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies (U.S.), Illumina, Inc. (U.S.), and Applied Spectral Imaging (U.S.).
Molecular Cytogenetics Market by Product (Kit, Reagent, Probe, Consumable, Software, Service), Technique (In-Situ, FISH, Comparative Genomic Hybridization), Application (Cancer, Genetic), End User (Research Labs, Institutes) - Forecast to 2021
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
Email: [email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE